These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 33011826

  • 1. In Mixed Lymphocyte Reaction, the Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat Suppresses Cellular and Humoral Alloimmunity.
    Eleftheriadis T, Pissas G, Mavropoulos A, Nikolaou E, Filippidis G, Liakopoulos V, Stefanidis I.
    Arch Immunol Ther Exp (Warsz); 2020 Oct 04; 68(6):31. PubMed ID: 33011826
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury.
    Yang Y, Yu X, Zhang Y, Ding G, Zhu C, Huang S, Jia Z, Zhang A.
    Clin Sci (Lond); 2018 Apr 16; 132(7):825-838. PubMed ID: 29581249
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Roxadustat attenuates experimental pulmonary fibrosis in vitro and in vivo.
    Huang H, Wang X, Zhang X, Wang H, Jiang W.
    Toxicol Lett; 2020 Oct 01; 331():112-121. PubMed ID: 32534005
    [Abstract] [Full Text] [Related]

  • 8. Activation of transcription factor HIF inhibits IL-1β-induced NO production in primary cultured rat hepatocytes.
    Yoshida T, Okumura T, Matsuo Y, Okuyama T, Michiura T, Kaibori M, Umezaki N, Bono H, Hirota K, Sekimoto M.
    Nitric Oxide; 2022 Jul 01; 124():1-14. PubMed ID: 35460897
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation.
    Miao AF, Liang JX, Yao L, Han JL, Zhou LJ.
    Ren Fail; 2021 Dec 01; 43(1):803-810. PubMed ID: 33966598
    [Abstract] [Full Text] [Related]

  • 13. The prolyl hydroxylase inhibitor roxadustat: Paradigm in drug discovery and prospects for clinical application beyond anemia.
    Su K, Li Z, Yu Y, Zhang X.
    Drug Discov Today; 2020 Jul 01; 25(7):1262-1269. PubMed ID: 32380083
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Treatment of Renal Anemia in Patients With Hemodialysis Using Hypoxia-inducible Factor (HIF) Stabilizer, Roxadustat: A Short-term Clinical Study.
    Mima A, Horii Y.
    In Vivo; 2022 Jul 01; 36(4):1785-1789. PubMed ID: 35738640
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. In human cell cultures, everolimus is inferior to tacrolimus in inhibiting cellular alloimmunity, but equally effective as regards humoral alloimmunity.
    Eleftheriadis T, Pissas G, Sounidaki M, Antoniadi G, Antoniadis N, Liakopoulos V, Stefanidis I.
    Int Urol Nephrol; 2017 Sep 01; 49(9):1691-1697. PubMed ID: 28508247
    [Abstract] [Full Text] [Related]

  • 20. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
    Besarab A, Provenzano R, Hertel J, Zabaneh R, Klaus SJ, Lee T, Leong R, Hemmerich S, Yu KH, Neff TB.
    Nephrol Dial Transplant; 2015 Oct 01; 30(10):1665-73. PubMed ID: 26238121
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.